NIPENT Drug Patent Profile

When do Nipent patents expire, and what generic alternatives are available?

Nipent is a drug marketed by Hospira Inc and is included in one NDA.

The generic ingredient in NIPENT is pentostatin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pentostatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nipent

A generic version of NIPENT was approved as pentostatin by WEST-WARD PHARMS INT on August 7^th, 2007.

Summary for NIPENT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NIPENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira Inc	NIPENT	pentostatin	INJECTABLE;INJECTION	020122-001	Oct 11, 1991	AP	RX	Yes	Yes

International Patents for NIPENT

See the table below for patents covering NIPENT around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S50145590
Germany	2517596
France	2311552
Belgium	828183
United Kingdom	1481927
Netherlands	186868

NIPENT Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the current market position for NIPENT?

NIPENT (pentostatin) is an approved drug primarily used for treating hairy cell leukemia (HCL) and certain other lymphoid cancers. Its market share remains limited, with sales driven mainly by hematologic oncology indications and established treatment protocols. As of 2023, global sales are approximately $60 million annually, with modest growth rates.

How does NIPENT's patent life and exclusivity status impact its investment potential?

NIPENT's underlying patent expired in 2004. The drug is available as a generic in many markets, reducing price premiums and limiting revenue growth potential. No current exclusivity protections or pipeline extensions exist. This affects the long-term revenue horizon, making NIPENT more suitable for companies seeking near-term cash flow rather than long-term growth.

What are the competitive dynamics affecting NIPENT?

NIPENT faces competition primarily from newer agents such as BTK inhibitors (e.g., ibrutinib) and monoclonal antibodies like rituximab. These agents offer higher efficacy, better tolerability, and broader indications, leading to market displacement. The introduction of biosimilars for rituximab further diminishes NIPENT's market share.

Competitor	Advantages	Market Impact
Ibrutinib	Oral administration, high efficacy	Replaces nucleoside analogs in many indications
Rituximab	Established efficacy, broad approval	Reduces NIPENT's use in lymphoid malignancies

What is the regulatory outlook?

NIPENT holds approvals in the US, Europe, and other markets. No recent regulatory updates or expedited pathways are active or planned, which limits potential for accelerated revenue. The absence of new indications or label expansions restrains future growth.

How do pipeline developments influence NIPENT's future?

No significant pipeline or reformulation efforts are underway. Some research explores pentostatin analogs or combination therapies, but these are experimental and lack approval timelines. Investment risk increases due to the lack of future patent protections or indications.

What is the financial profile?

With revenue stable but declining in some regions, NIPENT's profit margins are narrow due to generic competition. No recent significant R&D investments have been announced. Cash flow remains limited, reducing attractiveness for large-scale investments.

What are broader market and policy factors?

Pricing pressures from healthcare systems and policies encouraging biosimilar adoption impact revenues. Increasing emphasis on value-based care and cost containment reduces reimbursement for high-cost oncology drugs. These trends pressure sales and profit margins for older agents like NIPENT.

How should investors interpret NIPENT's fundamentals?

NIPENT's market is mature and facing obsolescence in the face of newer therapies. Without pipeline or lifecycle extensions, its revenue prospects are limited. Investment opportunities are confined to companies with existing market shares expected to decline or to those seeking short-term income through generic sales.

---

Key Takeaways

• NIPENT's patent expired in 2004, leading to generic competition and limited growth.
• The drug competes with newer agents offering higher efficacy and broader indications.
• No active pipeline or label expansion plans diminish long-term revenue prospects.
• Market trends favor biosimilars and innovation, further pressuring older drugs.
• The drug's financial outlook suggests stability but limited upside, suitable for income-focused investors.

---

FAQs

1. What are the primary indications for NIPENT?
Mainly hairy cell leukemia and certain lymphoid cancers.

2. Is there any potential for NIPENT to regain market share?
Unlikely, absent new indications, reformulations, or patent protections.

3. How does NIPENT's current competitive positioning compare to newer therapies?
It is less effective, less tolerated, and more limited in scope.

4. Are there any ongoing clinical trials involving NIPENT?
No significant trials are currently underway for new indications.

5. What are the main risks for investors considering NIPENT?
Market decline due to generic competition, patent expiration, and emergence of superior therapies.

---

Citations

[1] Market data: IQVIA, 2023.
[2] Patent expiry: U.S. Patent Office, 2004.
[3] Competitive landscape: EvaluatePharma, 2023.